Cover Image
close this bookTB/HIV: a Clinical Manual (WHO - OMS, 1996, 135 p.)
close this folderChapter 12 - Prevention of TB in HIV-infected individuals
close this folder12.3 The role of BCG in preventing TB in HIV-infected individuals
View the document12.3.1 Background
View the document12.3.2 BCG protection against TB in HIV-infected children
View the document12.3.3 BCG safety in HIV-infected children
View the document12.3.4 WHO recommended policy on BCG and HIV

12.3.1 Background

BCG (Bacille Calmette-Guerin) is a live attenuated vaccine derived originally from M. bovis. The route of injection is intra-dermal. The usual dose is 0.05 ml in neonates and infants under the age of 3 months, and 0.1 ml in older children. In high TB prevalence countries, WHO recommends a policy of routine BCG immunisation for all neonates shortly after birth.

The benefit of BCG is in protecting young children against disseminated and severe TB, e.g. TB meningitis and miliary TB. BCG has little or no effect in reducing the number of adult cases of PTB.